MassDevice caught Rob Campbell, Insulet Corp.‘s vice president of clinical research, on his way to dinner in Paris after a day spent lining up a distribution deal for the company’s flagship OmniPod insulin management system.

European Union regulators gave the nod for the device to hit the market there, meaning the Bedford-based diabetes device maker is cleared to start selling the OmniPod in countries that recognize the EU’s CE Mark.

“We were very pleased about the CE Mark, obviously,” Campbell told us, adding that he and vice president of international operations (and former CFO) Carsten Boess are making the rounds in Europe to arrange a distribution agreement. “We’ve been all over in the last two days — Germany, France, Scandinavia.”

The next stop for the young company, founded in 2000, is likely Asia, Campbell added.

“We’ve outgrown our manufacturing constraints in the U.S., which led us to look to outside markets,” he said. “There’s a long list outside of the EU, but the CE Mark certainly helps us with the establishment of markets in France and Germany.”

The OmniPod will be available in “selected markets” in Europe this year and more widely in 2010, according to a press release earlier today.

The device is a continuous insulin delivery system that uses a wireless, self-adhesive delivery device worn under clothing that connects to a hand-held programming device. It monitors blood sugar levels and delivers insulin to help regulate diabetic patients’ glucose levels.